Tag Archives: NASDAQ:REGN

The President & CEO of Regeneron is Exercising Options

Today it was reported that the President & CEO of Regeneron (REGN – Research Report), Leonard Schleifer, exercised options to buy 100 REGN shares at $21.25 a share, for a total transaction value of $2,125. Following Leonard Schleifer’s last REGN

Cantor Fitzgerald Sticks to Its Hold Rating for Regeneron (REGN)

Cantor Fitzgerald analyst Alethia Young reiterated a Hold rating on Regeneron (REGN – Research Report) yesterday and set a price target of $441. The company’s shares closed on Friday at $406.86, close to its 52-week high of $431.32. Young said:

Regeneron (REGN) Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Alethia Young from Cantor Fitzgerald assigned a Hold rating to Regeneron (REGN – Research Report), with a price target of $441. The company’s shares closed yesterday at $421.04, close to its 52-week high of $431.32.

Cowen & Co. Sticks to Their Hold Rating for Regeneron (REGN)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $385. The company’s shares opened today at $396.63, close to its 52-week high of

Oppenheimer Keeps a Buy Rating on Regeneron (REGN)

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of $440. The company’s shares closed on Friday at $365.65. Singh noted: “We met with members of the REGN mgmt

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and SeaSpine Holdings (NASDAQ: SPNE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report) and SeaSpine Holdings (SPNE – Research Report). Regeneron (REGN) J.P. Morgan analyst Cory Kasimov assigned a Hold rating